We used PI3Kγ inhibitor (AZD3458; 30 mg/kg administered orally, daily), TKI (lenvatinib; 10 mg/kg administered orally, daily) and ICI (anti-PD-1 mAb; 10 mg/kg intraperitoneally, daily). The results indicate that the PI3Kγ inhibitor specifically targets TAMs and alters their function to achieve anti-tumor effects. The findings of the study suggest that inhibiting PI3Kγ could be a crucial part of the combined anti-tumor treatment using ICI and TKI in HCC.

over 1 year ago

Combination therapy • PD(L)-1 Biomarker • IO biomarker

IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • PIK3CG (Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Gamma) • IL10 (Interleukin 10) • CCL2 (Chemokine (C-C motif) ligand 2) • IL23A (Interleukin 23 Subunit Alpha) • IL1B (Interleukin 1, beta)

Lenvima (lenvatinib) • AZD3458